MRNA241227P56000
- 19.54
- 0.000.00%
Moderna Newsroom
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
S&P 500: 2024 Stars, Flops, and What's Hot for 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
Palantir(PLTR.US) ranked top of the list had the largest change in short volume (51.06 million shares), and the short volume ratio of UL Solutions(ULS.US) reached 57.15%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Is Moderna Stock a Buy?
Moderna Options Spot-On: On December 19th, 214.79K Contracts Were Traded, With 705.56K Open Interest
On December 19th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 214.79K options for the day, of which put options accounted for 62.78% of the total transactions,
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
EST Dec 19th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Personalis Rallies Following $50 Million Investment From Merck, Extended Agreement With Moderna
Merck Buys $50 Million of Personalis Stock
Personalis Signs Multi-Year Extension With Moderna To Utilize Its ImmunoID NeXT Platform And Technology For V940/mRNA-4157
Express News | Personalis Inc: Merck Has Agreed to Purchase $50 Mln of Personalis Common Stock in a Private Placement at a Price of $3.56 per Share
Express News | Personalis Advances Business Strategy With Investment From Merck and Extends Collaboration With Moderna
California Gov. Newsom Declares State of Emergency Over Bird Flu
Moderna Lowered to Hold at Argus Amid Lower COVID Vaccine Sales, Competitive RSV Market
Moderna Analyst Ratings
Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
Worst Performing Stocks for Tax Loss Selling – Wolfe
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November